Clinical trials: Cancer Related Cardiovascular Toxicity
Anemia, Breast Cancer
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy.
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00003600
- Testing
- epoetin alfa
- Where
- 21 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cardiovascular Complication, Cardiovascular Insufficiency
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer…
- Conditions
- Cardiovascular Complication, Cardiovascular Insufficiency, Cardiac Complication, Oncologic Complications
- Trial name
- NEOCARDIO (NCT03882580)
- Testing
- Anti-Cancer Agents
- Where
- 3 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Cancer Therapy-related Cardiovascular Toxicity
Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
The purpose of this study was to explore the relationship between early myocardial injury caused by tumor drug therapy and intestinal microbial structure changes by echocardiographic two-dimensional speckle tracking technique and…
- Trial name
- NCT05730777
- Testing
- Bifidobacterium Bifidum Oral Capsule, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University Third Hospital
Coronary Artery Disease, Cardiac Disease
The CAROLE (CArdiac Related Oncologic Late Effects) Study
CAROLE seeks to evaluate the relationship between chest Radiation Therapy and coronary artery disease. The purpose of CAROLE is to check the heart health of women who received breast cancer treatments in the past and protect them…
- Conditions
- Coronary Artery Disease, Cardiac Disease, Cardiac Toxicity, Radiation
- Trial name
- CAROLE (NCT03235427)
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Northwell Health
Solid Carcinoma, 5-Fluorouracil Toxicity
Prevention of Chest Pain in Chemo-treated Cancer Patients
This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment…
- Conditions
- Solid Carcinoma, 5-Fluorouracil Toxicity, Cardiotoxicity, Chemotherapeutic Toxicity
- Trial name
- CATCH (NCT03486340)
- Testing
- Cardiologic assessment
- Where
- Denmark
- Volunteers
- 218 people
- Sponsor
- Vejle Hospital
Cancer Survivors, Cardiotoxicity
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
The BREATHS trial aims to investigate whether overnight in-bedroom air filtration reduces inflammation and cardiac biomarkers in adult survivors of cancer who are at high risk for cardiovascular complications.
- Conditions
- Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs
- Trial name
- BREATHS (NCT06778122)
- Testing
- High efficiency particulate air filtration system (nightly administration), High efficiency particulate air filtration system (nightly and daily administration)
- Where
- 3 sites in Spain
- Volunteers
- 10 people
- Sponsor
- University College, London
Breast Cancer, Cardiac Toxicity
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for…
- Conditions
- Breast Cancer, Cardiac Toxicity, Cardiovascular Complications
- Trial name
- PACE in BC (NCT00875238)
- Testing
- trastuzumab, doxorubicin hydrochloride, polymorphism analysis
- Where
- 4 sites in United States
- Volunteers
- 133 people
- Sponsor
- Vanderbilt University
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan
Cancer
Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial
The purpose of this study is to examine adherence to cardio-oncology consultation.
- Trial name
- CARMA (NCT05403736)
- Testing
- Cardiac Aggressive Risk MitigAtion Plan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Cancer, Drug Toxicity
Atrial Fibrillation in Active Cancer Patients
Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines.
- Conditions
- Cancer, Drug Toxicity, Atrial Fibrillation, Cardiovascular Complication
- Trial name
- AFIB-CANCER (NCT04696081)
- Testing
- occurence of atrial fibrillation
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Caen
Mucositis, Multiple Myeloma and Plasma Cell Neoplasm
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
RATIONALE: Studying blood or mouthwash samples in the laboratory from patients receiving melphalan for cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and help predict…
- Trial name
- NCT00602147
- Testing
- laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003937
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 148 sites in United States, Australia and 4 more
- Volunteers
- 253 people
- Sponsor
- Children's Oncology Group
Cancer, Breast, Cardiotoxicity
Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2)
Although great progress has been made in treating breast cancer, long-term health may be impaired by cancer therapy. For example, some chemotherapy drugs (e.g., anthracyclines) are known to cause declines in heart health.
- Conditions
- Cancer, Breast, Cardiotoxicity, Cardiovascular Diseases
- Trial name
- EXACT2 (NCT03748550)
- Testing
- Aerobic exercise
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Nova Scotia Health Authority
Breast Cancer, Cardiac Toxicity
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Breast Cancer, Cardiac Toxicity, Perioperative/Postoperative Complications
- Trial name
- NCT01093235
- Testing
- bevacizumab, cyclophosphamide, docetaxel
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Breast Neoplasms, Cardiotoxicity
The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.
This trial is to explore the optimal strategies for guaranteeing the cardiac safety of breast cancer patients following adjuvant radiotherapy in the modern era of multidisciplinary treatment.
- Trial name
- NCT02942615
- Testing
- limit heart dose
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Ruijin Hospital
Leukemia, Cardiac Toxicity
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
It is now accepted that the anticancer properties of anthracyclines were allowed in many malignancies improve the prognosis of affected populations.
- Trial name
- CA2D (NCT01212926)
- Testing
- Echographic analysis of myocardial deformation in 2D strain
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
Phase I trial to study the effectiveness of oblimersen plus combination chemotherapy and dexrazoxane in treating children and adolescents who have relapsed or refractory solid tumors.
- Trial name
- NCT00039481
- Testing
- oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Nephropathy
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients
Lung cancer is the leading cause of death worldwide, with non-small-cell lung cancer (NSCLC) being the most common histotype according to the global cancer observatory 2022.
- Conditions
- Non Small Cell Lung Cancer, Nephropathy, Cardiotoxicity
- Trial name
- NCT05746598
- Testing
- Cisplatin injection
- Where
- Egypt
- Volunteers
- 178 people
- Sponsor
- Ain Shams University
Cardiac Toxicity, Cancer
Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies
The goal of this observational study is to evaluate the cardiovascular health and prognosis of adult patients with cancer, treated with cardiotoxic therapies.
- Trial name
- CV_CANCER (NCT06664528)
- Testing
- ECHOCARDIOGRAPHY, ELECTROCARDIOGRAPHY (ECG), LABORATORY TESTS
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS